title: [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
authors.affiliation: Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen.
authors.forename: M
authors.initials: M
authors.lastname: Lehnen
authors.forename: M
authors.initials: M
authors.lastname: Goos
authors.forename: J
authors.initials: J
authors.lastname: Dissemond
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000209:etiology; D003879:Dermatologic Agents / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000737:chemistry / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept